Is a Low FODMAP Diet Good for Ulcerative Colitis?

A low FODMAP diet is a symptom treatment, not a colitis treatment. If your ulcerative colitis (UC) is in remission and you still get pain, bloating, wind and urgency, the trials say a short, structured FODMAP restriction has a reasonable chance of making you feel better. If you are hoping it will calm inflammation, keep you in remission or replace part of your treatment, the evidence does not stretch that far, and the most recent European consensus says so in plain terms.

That distinction is the whole answer, and it is the one that most pages about FODMAPs and UC skate over. This guide walks through what the UC-specific evidence actually shows, why the blinded trials look weaker than the open ones, the one biological trade-off that is unique to ulcerative colitis, why the diet is a poor idea during a flare, and how to run a trial that gives you a usable answer in six weeks instead of two years of shrinking your diet.

The short answer: good for symptoms, not for the colitis

Three claims get bundled into the question "is a low FODMAP diet good for ulcerative colitis", and they have completely different amounts of evidence behind them.

1. Does it reduce gut symptoms in people with UC in remission? Probably yes, for roughly half of people who try it properly. This is the claim the trials were designed to answer.
2. Does it reduce inflammation, calprotectin or disease activity? The pooled evidence says no.
3. Does it keep UC in remission? Nobody knows, because no trial has tested it.

The 2025 European Crohn's and Colitis Organisation consensus on dietary management of IBD is unusually blunt on the last two. Its Statement 12 says the low FODMAP diet is not recommended for maintenance of remission in Crohn's disease and that there is no evidence to support its use for maintenance of remission in ulcerative colitis, with 100% agreement among the panel. The accompanying text notes that no studies were identified that examined whether a low FODMAP diet can maintain remission in UC at all (Svolos 2025).

Two hundred lines later in the same document, Statement 20.1 says something that sounds contradictory until you read the wording: in adults with quiescent IBD and IBS-like symptoms, a low FODMAP diet is recommended to treat persistent gastrointestinal symptoms, graded at the highest evidence level and again with 100% agreement (Svolos 2025).

Both statements are true at once. One is about the disease. The other is about how you feel on a Tuesday. If you keep them apart, most of the confusion online disappears.

Why so many people with UC in remission still have symptoms

Because it is common, and because it is a different problem from colitis. Around a third of people with IBD in remission report symptoms that meet criteria for irritable bowel syndrome, and that is roughly three times the rate in the general population.

Pooling 27 studies and 3,169 people with IBD in remission, the prevalence of IBS-type symptoms was 32.5% overall and 28.7% in ulcerative colitis specifically. Crucially, the figure fell but did not vanish when remission was defined strictly: 23.5% when remission was confirmed endoscopically and 25.8% when confirmed histologically (Fairbrass 2020). So a quarter of people with a clean scope still have symptoms that look like IBS.

A thread in r/UlcerativeColitis captures the frustration exactly. Someone described six years and three or four colonoscopies, all reported as remission, while still having urgency, four to six loose stools a day and needing the bathroom twenty minutes after a meal. They had already tried cutting foods, cutting sugar, cutting alcohol and a FODMAP diet, and said their doctor kept telling them they were in remission so they did not know what they were supposed to be treating (r/UlcerativeColitis thread).

The mechanisms proposed for persistent symptoms after inflammation resolves include visceral hypersensitivity, changes in the enteric nervous system, central sensitisation, gut-brain axis dysregulation and psychosocial factors, rather than ongoing mucosal inflammation (Dell'Era 2026). A 2026 review of what clinicians now call IBD-IBS overlap adds lingering immune activation, disrupted barrier function and microbiome changes to that list (Chang 2026).

There is a wrinkle worth naming, because people in UC communities find the IBS comparison irritating for good reason. A post titled "I have IBS too!!" drew hundreds of upvotes from people tired of having a disease that can require surgery compared to a condition their colleague manages with peppermint tea (r/UlcerativeColitis thread). Both things can be true. UC and IBS are genuinely different, and you can have both at the same time, and the treatment offered for the second one is a diet built for IBS.

Rule out hidden inflammation before you restrict anything

This is the step that separates a useful FODMAP trial from a wasted one, and it is specific to having UC rather than IBS.

In a study of 106 people with IBD judged to be in remission by their physician, 38.6% of those with ulcerative colitis met Rome II criteria for IBS. But faecal calprotectin was significantly raised above the upper limit of normal in both disease groups, and was significantly higher in those who met IBS criteria than in those who did not. The authors concluded that in most cases the mechanism was likely occult inflammation rather than coexisting IBS (Keohane 2010).

Read that again before you cut out wheat. The symptom pattern that makes a low FODMAP diet look appealing is also the symptom pattern that has been associated with inflammation you cannot feel. If you restrict your diet, feel a bit better, and that low-grade inflammation carries on, you have bought comfort at the price of time.

The American Gastroenterological Association's guideline on biomarkers in UC suggests monitoring people in symptomatic remission with biomarkers plus symptoms rather than symptoms alone, and taking a closer look when biomarkers are raised in someone who feels well (Singh 2023). The American College of Gastroenterology recommends faecal calprotectin when relapse is suspected, noting it is more sensitive and specific than blood markers and less invasive than colonoscopy (Rubin 2025).

Practically, that means the order of operations is: talk to your IBD team, get objective confirmation that inflammation is controlled, and only then consider a structured dietary trial. Our guide to knowing whether your ulcerative colitis is flaring covers calprotectin thresholds, day-to-day variation and the first-morning sample rule in detail, so this article will not repeat them.

What the trials actually found in people with ulcerative colitis

Six studies carry most of the weight. They are worth walking through individually, because the headline "low FODMAP helps IBD" hides a very uneven picture.

The rechallenge trial. Twenty-nine people with quiescent IBD whose symptoms had already responded to a low FODMAP diet (17 of them with UC) were given blinded three-day challenges of fructans, galacto-oligosaccharides, sorbitol and a glucose placebo in random order. Only fructans made a difference: adequate symptom relief on the final day fell to 62.1% on fructans versus 89.7% on glucose, with more pain, bloating, flatulence and faecal urgency. GOS and sorbitol did not reliably provoke symptoms at the doses used (Cox 2017). This is the cleanest demonstration that fermentable carbohydrates cause real symptoms in this group, and it points at one FODMAP subgroup rather than all of them.

The main randomised trial. Fifty-two people with quiescent Crohn's disease or UC and persistent gut symptoms were randomised to a low FODMAP diet or a control diet for four weeks. More people reported adequate relief on the low FODMAP diet (14 of 27, 52%) than on the control diet (4 of 25, 16%). But the primary continuous measure, the change in IBS severity score, was 67 points on the low FODMAP diet versus 34 on the control, and that difference did not reach statistical significance. Quality of life was modestly higher. Markers of inflammation did not differ between the groups (Cox 2020).

The open-label Danish trial. Eighty-nine people with IBD in remission or with mild to moderate disease and coexisting IBS-like symptoms were randomised to a low FODMAP diet or a normal diet for six weeks, with no blinding. Eighty-one percent responded in the diet group versus 46% in the normal diet group, and quality of life rose more in the diet group (Pedersen 2017). Impressive numbers, and an open-label design in which everyone knew which arm they were in.

The Italian trial that reported a calprotectin change. Fifty-five people with IBD in remission or with mild activity were randomised to six weeks of a low FODMAP diet or a standard diet. Median faecal calprotectin fell in the diet group from 76.6 mg/kg to 50 mg/kg and did not fall in the standard diet group (Bodini 2019). This is the single result most often quoted as proof the diet reduces inflammation, so it is worth being careful: the starting value was already low, the endpoint sat at the bottom of the reporting range, the trial was small, and when the randomised trials are pooled the calprotectin effect is not there (Ville 2025, Peng 2022).

The clinical-practice series. Eighty-eight consecutive people with IBD and functional gut symptoms referred for low FODMAP education were compared before and after. Satisfactory relief rose from 16% to 78%, with improvements in stool form and frequency (Prince 2016). A before-and-after study with no control group, which the authors themselves said needed randomised confirmation.

The UC-only blinded study. Nineteen people with ulcerative colitis in remission and IBS symptoms went through eight weeks of open-label FODMAP elimination with two-week double-blinded crossover provocations of FODMAPs and placebo. Pain and bloating dropped significantly during the first two weeks of elimination, but there were no statistically significant differences in pain scores between the diet patients and the controls, and scores rose back towards baseline after the placebo provocations as well (Melgaard 2022). Recruitment was hard and the study was explicitly a feasibility exercise, so it cannot settle anything. It is still the closest thing to a blinded FODMAP trial conducted only in ulcerative colitis, and it is a reminder of how the effect shrinks when the design tightens.

Why the blinded trials look weaker than the open ones

Because diet trials are extremely hard to blind, and expectation does a lot of work in symptom outcomes. This is not a reason to dismiss the diet. It is a reason to be honest about the size of the effect you should expect.

Pooling nine studies and 446 participants, a low FODMAP diet improved overall functional gut symptoms in IBD (relative risk of symptoms not improving 0.47, 95% CI 0.33 to 0.66) and improved quality of life, with no significant difference in stool consistency, in the Mayo score of ulcerative colitis, or in faecal calprotectin (Peng 2022). An earlier meta-analysis of 319 people, 96% of them in remission, found improvements in diarrhoea, bloating, pain, fatigue and nausea, but not constipation (Zhan 2018).

A more sceptical systematic review looked at the same randomised trials and declined to pool them because of heterogeneity. It noted that calprotectin, CRP and T-cell phenotype did not differ between diet and comparator arms, that findings on stool frequency and short-chain fatty acids were inconsistent, and that in one trial energy intake was considerably reduced on the diet. Its conclusion was that the available data were not sufficient to justify the claim that the diet relieves functional symptoms, and that it may instead "pave the way to a placebo response" (Grammatikopoulou 2020).

A small UC-specific study makes the same point from a different direction. Thirty-one people with quiescent ulcerative colitis and IBS-like symptoms were randomised to 200 g a day of either a traditionally made bread or a control bread for eight weeks. IBS severity scores fell and abdominal pain reduced in both arms (Lluansi 2024). Whatever you conclude about bread, the useful lesson is that people in these trials tend to improve when someone gives them a structured plan and pays attention to them.

For comparison, the evidence base in IBS itself is stronger. A network meta-analysis of 13 randomised trials and 944 people with IBS found the low FODMAP diet ranked first for global symptoms against habitual diet (relative risk of symptoms not improving 0.67, 95% CI 0.48 to 0.91) and first for abdominal pain and bloating (Black 2022). British Society of Gastroenterology guidance positions it as a second-line dietary option in IBS, to be used if general lifestyle and dietary advice has not worked (Vasant 2021). So the honest framing for UC is: a treatment with good evidence in IBS, borrowed for the IBS-like symptoms that persist in UC remission, where the evidence is real but thinner.

The butyrate trade-off that only matters in ulcerative colitis

This is the part that makes the answer different for UC than for Crohn's disease or for IBS, and almost nobody mentions it.

Fructans and galacto-oligosaccharides are not just symptom triggers. They are prebiotics: the colon ferments them into short-chain fatty acids, and butyrate is the main respiratory fuel of the cells lining the colon. In ulcerative colitis, that fuel supply is already a known weak point. In a 1980 study of isolated colonocytes from people with quiescent and acute UC, oxidation of butyrate was significantly lower than in control tissue, and the degree of impairment tracked with disease state. The author proposed that UC might be, at least in part, an energy-deficiency disease of the colonic lining (Roediger 1980).

The bacteria that make butyrate are also depleted. Comparing 127 people with UC to 87 matched controls, both Roseburia hominis and Faecalibacterium prausnitzii were significantly lower in UC, both correlated inversely with disease activity, and short-chain fatty acids overall were reduced (Machiels 2014). In 116 people with UC in remission, low F. prausnitzii counts were associated with having been in remission for less than 12 months and with more than one relapse a year, and in a one-year follow-up the population recovered in those who stayed in remission but stayed low in those who relapsed (Varela 2013). That is an association, not proof that raising those bacteria prevents relapse, and no trial has shown that feeding them changes UC outcomes.

Now put the FODMAP trial next to it. In the randomised trial in quiescent IBD, four weeks of a low FODMAP diet significantly reduced faecal abundance of Bifidobacterium adolescentis, Bifidobacterium longum and Faecalibacterium prausnitzii compared with the control diet, although overall microbiome diversity and markers of inflammation did not differ (Cox 2020). The same direction of travel shows up elsewhere: in people with IBS, four weeks of fermentable carbohydrate restriction lowered the concentration and proportion of luminal bifidobacteria (Staudacher 2012), and in a controlled feeding crossover in Crohn's disease, the higher-FODMAP diet raised butyrate-producing Clostridium cluster XIVa and Akkermansia muciniphila relative to the low FODMAP diet, while doubling symptom severity (Halmos 2016).

That last study is a neat summary of the whole dilemma. The eating pattern that feeds the bacteria you would rather have is the one that makes you feel worse.

Why it is the wrong tool during a flare

No guideline recommends a low FODMAP diet for active ulcerative colitis, and the trials were all done in people in remission or with mild activity. Using it as a flare plan swaps a treatable problem for an untreated one.

The ECCO consensus is consistent on this point across several statements: neither low nor high fibre diets are recommended as maintenance therapy for Crohn's disease or ulcerative colitis, exclusive and partial enteral nutrition are not recommended as induction therapy for UC, and there is no evidence supporting the low FODMAP diet for maintenance of UC remission (Svolos 2025). The AGA practice update puts it plainly: no diet has consistently been found to decrease the rate of flares in adults with IBD (Hashash 2024). ESPEN similarly states there is no IBD diet that can be generally recommended to promote remission in people with active disease (Bischoff 2023).

The lived version of this appears repeatedly in UC communities. One long post described being handed a low FODMAP sheet by a gastroenterologist who said food did not matter, staying on the diet for months, feeling better for about a week and then much worse, and by the time the colonoscopy came round being largely housebound with mostly blood (r/UlcerativeColitis thread). Another described a flare of over a month, cutting out all fatty food and going strictly low FODMAP on advice, and narrowing down to chicken, rice and stewed fruit while things carried on (r/UlcerativeColitis thread). These are individual accounts, not evidence, but they describe a pattern worth naming: a restriction that feels like action, while the thing that needed treating carried on untreated.

Two practical points follow. First, if your stool frequency is climbing above your usual baseline, you are seeing blood, you are waking at night, or you feel systemically unwell, that is a call to your IBD team, promptly, not a reason to cut more foods. Our guide to whether food can trigger a UC flare covers the flare versus bad-symptom-day distinction in depth. Second, some people do find certain foods harder to tolerate while the colon is inflamed and easier again once inflammation is controlled. Adjusting temporarily with support is a different thing from running a diagnostic FODMAP protocol in the middle of active disease, when it cannot give you a clean answer anyway.

What people get wrong about lactose and wheat in UC

Two of the biggest FODMAP groups get eliminated permanently by a lot of people with ulcerative colitis, usually on the basis of a bad week rather than a test. The prevalence data do not support doing that automatically.

Lactose. In 54 people with IBD in clinical remission and 69 matched controls, hydrogen breath testing was positive in 64.8% of the IBD group and 62.3% of controls, a difference that was not significant, and the distribution of lactase gene variants was similar in both groups. The authors concluded that about a third of people with IBD who have suggestive symptoms are not actually lactose intolerant and do not need an elimination diet started in advance of testing (Nardone 2021).

Fructose. In a multicentre study of 205 people, fructose malabsorption on breath testing was found in 79.6% with active IBD, 73.8% with inactive IBD and 81.5% of healthy controls, with no significant difference between groups. What did differ was symptoms: abdominal pain was more frequent during testing in those with active IBD than in those in remission (Helwig 2021). Malabsorption is close to universal. Whether it produces symptoms is the variable part, and that is a sensitivity question, not an absorption one.

Wheat. Fructans, the FODMAP group in wheat, onion and garlic, are the one group with a blinded provocation signal in this population (Cox 2017). That is a reason to test wheat carefully during reintroduction. It is not the same as a gluten problem, and the two get conflated constantly. One person in r/UlcerativeColitis described going gluten free as part of going low FODMAP during their worst flare, then being unable to tell months later whether the occasional loose stools on reintroduction meant anything (r/UlcerativeColitis thread). That is what happens when a restriction starts during active disease: there is no clean baseline to compare against.

Beliefs about food in IBD run well ahead of the testing. In a survey of 400 people attending IBD clinics, 60% reported worse symptoms with certain foods and 66% had given up favourite foods to try to prevent relapse, while nearly half had never received formal dietary advice (Limdi 2016). A structured trial with planned reintroduction exists precisely to shrink that gap.

If you have had surgery, the answer changes

This is where ulcerative colitis and irritable bowel syndrome part company completely. A low FODMAP diet works on the logic that poorly absorbed carbohydrates draw water into the small bowel and are fermented in the colon. After a colectomy with an ileo-anal pouch, the colon that does that fermenting is gone.

The evidence in pouches is thin and does not point where you might expect. In a cross-sectional study of 58 people with an ileoanal pouch, 81% of those whose pouch followed ulcerative colitis reported dietary intolerances, but overall diet quality was good and perceived intolerances had minimal effect on nutritional adequacy. On multivariable analysis, higher dietary fibre intake was associated with lower odds of a history of pouchitis (odds ratio 0.68, 95% CI 0.51 to 0.92) while higher intake of non-digestible oligosaccharides, the FODMAP group, was associated with higher odds (odds ratio 5.5, 95% CI 1.04 to 29.1) (Ardalan 2023). Those are associations from a small cross-sectional study with very wide confidence intervals, and the authors said they require further study before they inform dietary recommendations.

Attempts to test a whole-diet strategy in pouches have gone badly. A randomised, double-blind, placebo-controlled feeding trial of a pouch-specific diet in people with symptomatic pouches was terminated early because all patients on the intervention diet experienced worsening symptoms, with poor tolerability and partial adherence (Ardalan 2025). The ECCO consensus notes an open-label low FODMAP study in five pouch patients with variable results, and that non-fermentable fibre in the form of methylcellulose gave no symptomatic benefit in a crossover study (Svolos 2025).

If you have a pouch or an ileostomy, treat everything written about FODMAPs and UC as written about a different organ arrangement, and take dietary questions to your surgical and dietetic team rather than to a food list.

How to run a FODMAP trial that gives you a usable answer

If your IBD team agrees inflammation is controlled and you both want to test the symptom question, structure matters more than strictness. A well-run six-week trial beats two years of slow, unplanned shrinking.

Before you start.

• Get objective confirmation that inflammation is controlled, typically faecal calprotectin, with your IBD team (Singh 2023).
• Ask for a referral to a dietitian with IBD experience. ECCO states that all people with IBD should have access to one (Svolos 2025), the AGA suggests all newly diagnosed patients have access to a registered dietitian (Hashash 2024), and the guidance to monitor and customise the diet with a dietitian is explicitly there to prevent ongoing over-restriction.
• Record two weeks of your usual eating and symptoms first. Without a baseline you will be comparing a restricted diet to a memory.

Restriction phase, four to six weeks. That is the length used in the trials: four weeks in the main randomised trial (Cox 2020), six in two others (Pedersen 2017, Bodini 2019). If nothing has changed by the end of it, that is your answer. Going stricter is not the next step.

Reintroduction, which is the point of the exercise. Reintroduce FODMAP groups one at a time, in planned challenges, and keep the ones you tolerate. Long-term follow-up in IBS shows this works: of 103 people followed up after dietitian-led education, 57% still had satisfactory symptom relief long term, and 82% were on a personalised "adapted FODMAP" diet rather than full restriction, with nutritional adequacy maintained (O'Keeffe 2018). Fructans are the group worth testing most carefully in this population, because they are the one with a blinded provocation signal (Cox 2017).

Stop rules, agreed in advance. Stop and contact your IBD team if blood appears, if stool frequency rises above your baseline for more than a couple of days, if symptoms wake you at night, or if you lose weight unintentionally. Stop the restriction phase if six weeks has produced no change, or if you notice your food list narrowing beyond the protocol.

A note on the practicalities, because they are not trivial. In the long-term IBS follow-up, people on the adapted diet reported that it cost significantly more than a habitual diet and affected social eating (O'Keeffe 2018). The workarounds people share are real and useful: garlic-infused oil and the green parts of spring onions come up constantly in UC threads as a way to keep food tasting like food (r/UlcerativeColitis thread).

A worked example: eight weeks, one clear answer

Where Dan starts. Dan has left-sided UC, has been on maintenance treatment for two years, and his last colonoscopy was clear. He still gets bloating that builds through the afternoon, wind that he describes as constant, and two or three days a month of urgency that makes him plan his commute around toilets. No blood, no night-time symptoms, weight stable.

Weeks 1 and 2: baseline and a test. Dan logs every meal, stool form and frequency, urgency episodes, any blood, and whether symptoms wake him. He also notes sleep, stress and any painkillers. His IBD nurse arranges a first-morning faecal calprotectin, which comes back in his normal range. That result is what makes the next six weeks worth doing: without it, any improvement would be uninterpretable.

Weeks 3 to 6: restriction. With a dietitian, Dan restricts FODMAPs for four weeks. By the end of week four his bloating score has roughly halved and he has had one urgency day instead of three. His stool frequency is unchanged, which matches what the trials found about stool consistency and frequency (Peng 2022).

Weeks 7 and 8: reintroduction, one group at a time. Lactose goes back in with no effect, which fits the breath-test data showing lactose intolerance is no more common in IBD than in controls (Nardone 2021). Sorbitol goes back in with no effect. Fructans reproduce the bloating within a day, twice, which is the group with the blinded evidence behind it (Cox 2017).

Where Dan lands. He eats a normal diet with a portion ceiling on onion, garlic and large servings of wheat, rather than a permanently restricted one. He has added back roughly 80% of what he cut. If instead nothing had changed by week six, the correct move would have been to stop and take the log back to his IBD team, not to cut more.

Keeping that kind of record by hand works. Clairop is built for it: you log a meal by speaking or by scanning a barcode, and it compares your symptoms after meals with and without a given food across delay windows, then puts your activity score, bowel pattern and medication adherence on a one-page summary for your appointment. The method page explains why it waits for at least five meals with and without a food before showing anything, which is the same reason a single reaction is not a trigger. For the diary mechanics themselves, our guide to keeping a food diary covers what to write down and when.

The risks worth weighing before you start

A low FODMAP diet is a real intervention with real costs, and in ulcerative colitis those costs land on top of a disease that already carries nutritional risk.

Over-restriction is the common failure mode. In a clinic study of 161 people with IBD, 92% avoided at least one food while symptomatic and 74% kept avoiding foods even when symptom-free. Seventeen percent screened positive for avoidant restrictive food intake disorder, and that group was much more likely to be at risk of malnutrition (Yelencich 2022). If you notice food fear creeping in, our article on whether the low FODMAP diet can cause an eating disorder covers the warning signs and how to do a trial with less risk.

Nutritional adequacy depends on doing it properly. Reviews of the diet flag reduced intakes of calcium, iron and fibre as risks when it is done without support, alongside the microbiological and psychosocial effects (Staudacher 2017), while the long-term follow-up with dietitian-led education found adequacy was maintained (O'Keeffe 2018). The difference between those two outcomes is supervision. Iron matters more in UC than in IBS because of blood loss: ECCO states that haemoglobin and iron status should be monitored in everyone with IBD (Svolos 2025), and the AGA says all patients with IBD should be monitored for vitamin D and iron deficiency (Hashash 2024).

Eating less to feel better has its own cost. One of the randomised trials reviewed found energy intake was considerably reduced on the diet (Grammatikopoulou 2020). In a disease where unintentional weight loss is a warning sign, feeling better because you are eating less is not a win, and it is worth being honest with yourself about which of the two is happening.

What else is on the table for IBS-type symptoms in UC

Diet is one lever among several, and it is worth knowing the others before you commit months to a food protocol.

Gut-brain therapies. These are widely recommended for IBS, and the evidence in IBD specifically is mixed. In a randomised trial of 80 people with IBD in clinical and biochemical remission and IBS by Rome III criteria, gut-directed hypnotherapy was not superior to standard medical treatment: the primary outcome was met by 30% on hypnotherapy and 27% on standard treatment (Hoekman 2021). The authors concluded both were reasonable clinical options, which is a more honest summary than the enthusiasm this area often attracts.

Other dietary components. ECCO looked at fibre for this exact problem and found insufficient evidence to support high-fibre foods, fibre supplements or a low-fibre diet for treating persistent gut symptoms in quiescent IBD (Svolos 2025). For general eating, the AGA advises a Mediterranean-style pattern rich in fruit, vegetables, complex carbohydrates and lean proteins and low in ultra-processed food, for overall health (Hashash 2024).

Multimodal care. Recent reviews of IBD-IBS overlap describe combining medication aimed at the symptom pattern, dietary work, mind-body therapies and microbiome-directed strategies rather than picking one (Chang 2026). Given that anxiety and depression scores are significantly higher among people with IBD who report IBS-type symptoms than among those who do not (Fairbrass 2020), the psychological side of this is not an afterthought.

Any decision about medication, including starting, stopping or changing anything, belongs with your IBD team rather than a diet plan.

Myths worth dropping

Myth: "Low FODMAP is an anti-inflammatory diet." It is not. Pooled randomised trials found no effect on ulcerative colitis disease activity and none on faecal calprotectin (Ville 2025), and the trial that measured circulating inflammatory markers found no difference between groups (Cox 2020).

Myth: "If it helps my symptoms, my UC must be quiet." Feeling better is not the same as inflammation being controlled. People with IBD in apparent remission who met IBS criteria had higher calprotectin than those who did not (Keohane 2010), which is why testing comes first and stays part of monitoring (Singh 2023).

Myth: "Everyone with UC should avoid dairy and wheat." Lactose intolerance on breath testing was no more common in IBD than in matched controls (Nardone 2021), and fructose malabsorption was no more common either (Helwig 2021). Blanket elimination costs you food variety and gives you no information.

Myth: "If four weeks did not work, I did not go strict enough." In the randomised trials the diet helped about half the people who tried it, and the difference on the main continuous symptom measure was not statistically significant (Cox 2020). Not responding is a normal result, and it means look elsewhere.

Myth: "Staying on it forever is the safe option." It reduces Faecalibacterium prausnitzii and bifidobacteria (Cox 2020, Staudacher 2012), and F. prausnitzii is already depleted in UC and associated with shorter remission (Machiels 2014, Varela 2013). Long-term restriction is also associated with restrictive eating patterns and malnutrition risk in IBD (Yelencich 2022).

Myth: "It is worth a go during a flare, it cannot hurt." It has never been tested for active UC, no guideline supports it (Svolos 2025, Bischoff 2023), and the time spent restricting is time not spent getting the inflammation assessed.

Myth: "A low FODMAP diet works the same way after pouch surgery." The fermentation compartment is different. What evidence exists in pouches is limited, inconsistent and in one study pointed towards higher fibre being associated with less pouchitis history (Ardalan 2023).

When to contact your IBD team

Contact your IBD team promptly, rather than adjusting your diet on your own, if anything suggests active inflammation. A dietary change should never be used to ride out these symptoms.

Contact your IBD team promptly if you have:

• New blood in your stool, or more blood than usual
• Stool frequency rising above your usual baseline for more than a couple of days
• Symptoms that wake you at night
• New or worsening abdominal pain
• Unintended weight loss, or eating much less because of symptoms
• Feeling unusually tired or breathless, which can be a sign of anaemia
• A recent stomach bug, a course of antibiotics, or regular use of anti-inflammatory painkillers alongside worsening symptoms

Seek urgent same-day medical help if you have:

• More than six bloody stools a day
• A fever, a racing heart, or feeling faint
• Signs of dehydration, such as passing very little urine, dizziness on standing, or being unable to keep fluids down
• Severe abdominal pain, or a swollen, tender abdomen

The ACG guideline describes acute severe ulcerative colitis as six or more bloody stools a day with at least one sign of systemic illness, such as fever, a fast heart rate, anaemia or raised inflammatory markers, and advises hospital admission (Rubin 2025). That is not something to manage at home with a food list.

When you do speak to your team, bring specifics: how many stools a day compared with your normal, days with blood, night-time episodes, any weight change, and where you are in any dietary trial. If you have been restricting for months, say so, because it changes both how your symptoms should be interpreted and what nutritional checks are worth doing. For more on tracking UC and working with your team, browse our ulcerative colitis guides.